![PDF) Genexpressionsanalyse primär resezierter Dünndarmkarzinome: Zusammenhang zwischen Prostaglandinsynthasen (COX-1, COX-2, mPGES), TGF-β β1 und Angiogenese (VEGF-A und C) (Abstract 69). PDF) Genexpressionsanalyse primär resezierter Dünndarmkarzinome: Zusammenhang zwischen Prostaglandinsynthasen (COX-1, COX-2, mPGES), TGF-β β1 und Angiogenese (VEGF-A und C) (Abstract 69).](https://i1.rgstatic.net/publication/305033615_Genexpressionsanalyse_primar_resezierter_Dunndarmkarzinome_Zusammenhang_zwischen_Prostaglandinsynthasen_COX-1_COX-2_mPGES_TGF-b_b1_und_Angiogenese_VEGF-A_und_C_Abstract_69/links/577f849f08ae5f367d36f3ed/largepreview.png)
PDF) Genexpressionsanalyse primär resezierter Dünndarmkarzinome: Zusammenhang zwischen Prostaglandinsynthasen (COX-1, COX-2, mPGES), TGF-β β1 und Angiogenese (VEGF-A und C) (Abstract 69).
![Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-06-00988/article_deploy/html/images/pharmaceuticals-06-00988-g007.png)
Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML
![PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement](https://i1.rgstatic.net/publication/8467805_Predicting_Early_Failure_after_Adjuvant_Chemotherapy_in_High-Risk_Breast_Cancer_Patients_with_Extensive_Lymph_Node_Involvement/links/00b4952c189289fc5d000000/largepreview.png)
PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement
![Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-06-00988/article_deploy/html/images/pharmaceuticals-06-00988-g006-1024.png)
Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML
![Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. - Abstract - Europe PMC Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3817731/bin/pharmaceuticals-06-00988-g004.jpg)
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. - Abstract - Europe PMC
![PDF) Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1 PDF) Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1](https://i1.rgstatic.net/publication/24233988_Dispensable_role_of_protein_41BDAL-1_in_rodent_adrenal_medulla_regarding_generation_of_pheochromocytoma_and_plasmalemmal_localization_of_TSLC1/links/5bd6c9c7a6fdcc3a8dadb14a/largepreview.png)
PDF) Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1
![Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-06-00988/article_deploy/html/images/pharmaceuticals-06-00988-g009.png)
Pharmaceuticals | Free Full-Text | Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action | HTML
![IJMS | Free Full-Text | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions | HTML IJMS | Free Full-Text | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions | HTML](https://www.mdpi.com/ijms/ijms-20-04543/article_deploy/html/images/ijms-20-04543-g001-550.jpg)
IJMS | Free Full-Text | Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions | HTML
![PDF) Abstract 46: Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients PDF) Abstract 46: Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients](https://i1.rgstatic.net/publication/262381514_Abstract_46_Loss_of_CADM1_expression_is_associated_with_poor_prognosis_and_brain_metastasis_in_breast_cancer_patients/links/544e17f90cf29473161a1525/largepreview.png)
PDF) Abstract 46: Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients
![PDF) Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway PDF) Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway](https://i1.rgstatic.net/publication/353460667_Ruxolitinib_Combined_with_Gemcitabine_against_Cholangiocarcinoma_Growth_via_the_JAK2STAT13ALDH1A3_Pathway/links/60fec322169a1a0103baf734/largepreview.png)
PDF) Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
![PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement](https://www.researchgate.net/profile/Elsken-Wall/publication/8467805/figure/fig3/AS:667201518448640@1536084646161/IHC-of-MRPs-in-controls-and-breast-cancer-cell-lines_Q320.jpg)
PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement
![PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement PDF) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement](https://www.researchgate.net/profile/Elsken-Wall/publication/8467805/figure/tbl10/AS:667201518465040@1536084646415/BCRP-expression-measured-in-controls-and-breast-cancer-cell-lines_Q320.jpg)